The Motley Fool Discussion Boards

Previous Page

CAPS / CAPS Blogs

URL:  https://boards.fool.com/it39s-important-to-note-that-in-the-reference-34333577.aspx

Subject:  Re: A BAKER'S DOZEN & A HORSE OF A DIFFERENT Date:  11/2/2019  10:04 AM
Author:  MightyMaven Number:  265 of 424

It's important to note that in the reference work above, for success rates for going from Phase 3 to NDA/BLA phase via successful completion, the Chronic High Prevalence Conditions average is success rate is 61%, and the Rare Diseases Condition is 73% success rate. That's 3 to 1 odds, this last one.

* NDA new drug application
* BLA biologic license application
Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us